Lanreotide Autogel/Depot (LAN) Post-Octreotide Long-Acting Release (OCT) for Safe and Tolerable Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 13
页数：2
相关论文
共 50 条
  • [1] Lanreotide Autogel/Depot (LAN) Post-Octreotide Long-Acting Release (OCT) for Safe and Tolerable Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Saif, M. Wasif
    Fu, Julie
    Smith, Melissa
    Maloney, Antonia
    Relias, Valerie
    JWeinstein, Barbara
    Suarez, Yvelisse N.
    Goodman, Martin D.
    Daly, Kevin P.
    PANCREAS, 2017, 46 (03) : 436 - 436
  • [2] The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Saif, Wasif M.
    Parikh, Rohan
    Ray, David
    Kaye, James A.
    Kurosky, Samantha K.
    Thomas, Katharine
    Beveridge, Thomas
    Mirakhur, Beloo
    Lubeck, Catherine A.
    Nagar, Saurabh P.
    Soares, Heloisa
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] The Sequencing of Lanreotide (LAN) After Octreotide LAR (OCT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Saif, Wasif M.
    Parikh, Rohan C.
    Ray, David
    Kaye, James A.
    Kurosky, Samantha K.
    Thomas, Katharine
    Halfdanarson, Thorvardur R.
    Beveridge, Thomas
    Mirakhur, Beloo
    Lubeck, Catherine A.
    Nagar, Saurabh
    Soares, Heloisa
    PANCREAS, 2019, 48 (03) : 450 - 450
  • [4] Comparative Analysis of Octreotide Long Acting Release (LAR) and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Single Institution Experience
    Wu, S.
    Reta-Impey, P.
    Manivannan, N.
    Tirumani, S. H.
    Fu, P.
    Cao, S.
    Asa, S.
    Kardan, A.
    Liu, F.
    Avril, N.
    Wojtylak, P.
    Lee, R.
    Bajor, D.
    Selfridge, E.
    Saltzman, J.
    Hardacre, J.
    Ammori, J.
    Winter, J.
    Mohamed, A.
    PANCREAS, 2021, 50 (03) : 448 - 449
  • [5] Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Saif, Muhammad Wasif
    Fu, Julie
    Smith, Melissa H.
    Weinstein, Barbara
    Relias, Valerie
    Daly, Kevin P.
    JOURNAL OF PANCREATIC CANCER, 2018, 4 (01): : 64 - 71
  • [6] Evaluation of unreimbursed costs in the UK through utilisation of home administration of lanreotide autogel (LAN) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Higgs, K.
    Halpin, C.
    Bolton, R.
    Frankcom, I
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 86 - 86
  • [7] Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 11 - 12
  • [8] OPERA: Observational study of perception of information and quality of life (QoL) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) starting Lanreotide Autogel (LAN)
    Hautefeuille, V
    Walter, T.
    Do Cao, C.
    Coriat, R.
    Dominguez, S.
    Mineur, L.
    Gueguen, D.
    Houchard, A.
    Mouawad, C.
    Anota, A.
    Hammel, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 136 - 136
  • [9] ELECT: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel (LAN) Treatment for Carcinoid Syndrome (CS) in Patients (Pts) with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Gomez-Panzani, E.
    Vinik, A.
    Wolin, E.
    Audry, H.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 271 - 271
  • [10] Long-acting lanreotide in the treatment of neuroendocrine tumors (NETs)
    Antonuzzo, A
    Ricci, S
    Galli, L
    Conte, PF
    ANNALS OF ONCOLOGY, 1998, 9 : 175 - 175
12345